



SCAN TO VERIFY

AX-2026-1074-QP6V

 TB-500 (Thymosin B4) · Lot T-TB5-0084
 Issued Oct 1, 2026 · v1
 Verify: 4CC8-1A08-66D4

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

 ■ L1
 Identity

 ■ L2
 Purity

 ■ L3
 Net Peptide Content

 ■ L4
 Sterility

 ■ L8
 Fentanyl Screen

Sample & Vial Validation


Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A - right

Client	NU Biotech Labs	Product	TB-500 (Thymosin B4)
Lot / Batch	T-TB5-0084	Label Claim	10 mg
Matrix	lyophilized powder	Sample Count	1
Cap Color	Black	Crimp Color	Silver / Aluminum
Contents Color	White	Seal Intact	Yes
Condition	sealed, intact	Received	Sep 24, 2026
Sampling	client submitted		

Test Results

Test	Specification	Result	
Identity research screen	every vial within ± 1 Da of 4963.506 Da	4963.643 Da	PASS
Purity research screen	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.75%	PASS
Net Peptide Content research screen	every vial within $\pm 10\%$ of 10 mg	Vial A: 10.35 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS

Layer Results



SCAN TO VERIFY

AX-2026-1074-QP6V

 TB-500 (Thymosin B4) · Lot T-TB5-0084
 Issued Oct 1, 2026 · v1
 Verify: 4CC8-1A08-66D4

1 Identity

LC-MS (ESI+)

1 physical-vial mass observation

each +/- 1 Da (theor. 4963.506)

PASS

Mass consistent with TB-500 (Thymosin B4)

 Theoretical mass **4963.506 Da** Acceptance **+/- 1 Da**

Vial	Observed mass	Mass error	Status
Vial A	4963.643 Da	+0.137 Da	PASS

 4963.643 Da **PASS**
2 Purity

RP-HPLC 214nm (USP 621)

Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31

1 physical-vial purity observation
PASS

Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31

Vial	Purity	Status
Vial A	99.75%	PASS

 99.75% **PASS**

limit 99.25%

3 Net Peptide Content

Quantitative HPLC vs reference std

10.35 mg

each within +/- 10% of 10 mg

PASS

 10.35 mg **PASS**

Vial	Measured	Status
Vial A	10.35 mg	PASS

4 Sterility

Rapid Microbial DNA Screen (qPCR target panel)

Sterility · Rapid PCR: Target DNA not detected

No microbial target DNA detected

PASS
Sterility · Rapid PCR
PASS

Result	Target DNA not detected	Specification	Rapid PCR screen
--------	--------------------------------	---------------	-------------------------



AX-2026-1074-QP6V

TB-500 (Thymosin B4) · Lot T-TB5-0084
Issued Oct 1, 2026 · v1
Verify: 4CC8-1A08-66D4

8

Fentanyl Screen

LC-MS/MS targeted adulterant screen

Not detected

detection limit 1 ng/mg

PASS

Analytes
screened

**Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl,
Carfentanil, Cyclopropylfentanyl, Furanylfentanyl,
Methoxyacetylfentanyl, ortho-Fluorofentanyl,
Valerylfentanyl, 4-ANPP (despropionyl fentanyl)**

Detection limit

1 ng/mg

Source container

A

Reporting Scope & Limitations

[Sterility · Rapid PCR] DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

[Fentanyl Screen] Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

Digital Signatures

Analyst

Alana Reeves

Analyst Signature

ed25519:8439d319b1669bfc0d5959df...

Technical Reviewer

Michael Niles

Reviewer Signature

ed25519:69affb06bbf0bc3baa57743c...

Laboratory Director

Daniel Brennan

Director Signature

ed25519:d22323a73bcdaffc2ed708d4...

Physical instrument analysis is performed within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: samples are analyzed under double-blind conditions, identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at <https://axiomanalyticslab.com/verify/AX-2026-1074-QP6V>.

✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: 99961ad0b8e33227676c0a6b5bbe29607e62e1bd2b530b73ec7d50960ddad6e6...

Seal: ed25519:cc23128a2023aed73fcee9a32161c5e5c3fd87...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.